ALG-055009 clinical trials
Also written ALG-055009.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses ALG-055009 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALG-055009
- 4
Studies by the year they started
4 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Who runs them
Industry 4 · Other 0
Aligos Therapeutics (4)
Studies
Open first, then newest update. How each study uses ALG-055009 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 FormulationsCompletedPhase 1Aligos TherapeuticsNCT06959888Written as ALG-055009
- A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)CompletedPhase 1Aligos TherapeuticsNCT06191991Written as ALG-055009
- ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)CompletedPhase 2Aligos TherapeuticsNCT06342947Written as ALG-055009
- A Study of ALG-055009 in Healthy Volunteers and Subjects With HyperlipidemiaCompletedPhase 1Aligos TherapeuticsNCT05090111Written as ALG-055009